Elsevier Acquires Windhover Information Inc., a Healthcare Business Intelligence Company
Share:
Acquisition Extends Elsevier's Ability to Gather Global Healthcare News and add to it in-Depth Analysis and Commentary That Will Dramatically Increase Business Value for Customers
PHILADELPHIA, March 10 -- Elsevier, the world's leading publisher of science, technical and health information, announced today that it has acquired Windhover Information Inc., a healthcare business intelligence company that provides analysis and commentary on healthcare business strategy, industry deal making, marketplace trends and medical start-ups.
The acquisition supports Elsevier's e-Health strategy to improve patient healthcare and the business of health in the Pharma business intelligence market. It expands Elsevier's offering of new products and services for Pharma industry professionals by combining innovative technology and industry-leading content to promote faster and better informed planning and management of product portfolios.
"Adding Windhover's expert analysis of the pharmaceutical and medical device industries to our existing regulatory and general business news services and database expands both the depth and breadth of Elsevier's customer offerings," said Brian Nairn, CEO of Elsevier Health Sciences.
"Windhover also provides an exciting platform for new products."
Windhover produces authoritative journals such as IN VIVO and the RPM Report, the world's most comprehensive database of healthcare industry transactions (Strategic Transactions Database), and a series of medical-device and biopharmaceutical partnering and strategy conferences.
With Windhover, Elsevier will field a team of more than 100 journalists in bureaus covering healthcare developments across the globe.
The acquisition of Windhover is Elsevier's latest in a series of highly synergistic investments in content, workflow tools and e-Health services. Windhover will operate within Elsevier's Pharma Business Intelligence Unit, which includes F-D-C Reports, Inc. (including "The Pink Sheet" and "The Gray Sheet") and Inteleos, a powerful drug development database.
"Elsevier is one of the few companies as dedicated to covering the business of healthcare as Windhover is," said Roger Longman and David Cassack, Managing Partners and co-founders of Windhover. "We're proud to align with The Pink Sheet and other F-D-C Reports products and provide growth opportunities for our staff."
Terms of the acquisition are not being disclosed.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as Science Direct. (http://www.sciencedirect.com/), MDConsult (http://mdconsult.com/), Nursing Consult (http://www.nursingconsult.com/) Scopus (http://www.info.scopus.com/), bibliographic databases, and online reference works.
Elsevier (http://www.elsevier.com/) is a global business
headquartered in Amsterdam, The Netherlands and has offices worldwide.
Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a
world-leading publisher and information provider. Operating in the science
and medical, legal, education and business-to-business sectors, Reed Elsevier
provides high-quality and flexible information solutions to users, with
increasing emphasis on the Internet as a means of delivery. Reed Elsevier's
ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK
and ENL (New York Stock Exchange).
Tom Reller
Director of Corp. Relations, Elsevier
+1-212-462-1912
T.Reller@Elsevier.com
Source: Elsevier
